Attached files
| file | filename |
|---|---|
| 8-K/A - 8-K -VIBATIV FINANCIAL STATEMENTS - CUMBERLAND PHARMACEUTICALS INC | a8kaforvibativfs.htm |
| EX-99.3 - EXHIBIT 99.3 PROFORM - CUMBERLAND PHARMACEUTICALS INC | exhibit993.htm |
| EX-99.2 - EXHIBIT 99.2 2018 VIBATIV SPF - CUMBERLAND PHARMACEUTICALS INC | exhibit992.htm |
| EX-99.1 - EXHIBIT 99.1 2017 VIBATIV SPF - CUMBERLAND PHARMACEUTICALS INC | exhibit991.htm |
Exhibit 23.1
Consent of Independent Auditors
We hereby consent to the incorporation by reference in the Registration Statements on Form S-3 (No. 333-221402) and Form S-8 (No. 333-164376) of Cumberland Pharmaceuticals Inc. of our report dated January 11, 2019, relating to the special purpose financial statements of the VIBATIV Product Line of Theravance Biopharma, Inc., which appears in this Current Report on Form 8-K/A of Cumberland Pharmaceuticals Inc.
/s/ Ernst & Young LLP
San Jose, California
January 23, 2019